Affirms FY23 revenue view of $124M-$128M, consensus $131.2M. The increase in EPS guidance is “driven primarily by additional gains realized from the sale of Viking Therapeutics securities. Due to the unpredictable nature of the pandemic and related Captisol sales, Ligand excludes Captisol sales related to COVID-19 from guidance and will update investors as orders are received and shipped each quarter.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LGND:
- Is LGND a Buy, Before Earnings?
- Ligand says Merck reports V116 met key endpoints in two Phase 3 trials
- Ligand price target lowered to $110 from $120 at Barclays
- Ligand offers to acquire Novan for $15M in cash, $15M in financing
- Novan to sell substantially all assets for $15M, files for Chapter 11 protection